Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
BackgroundPoly (ADP-ribose) polymerases-1 (PARP1) alterations are associated with PARP1 inhibitor resistance, regulating the function of Treg cells and PDL1 expression in tumor cells, and high PARP1 expression is significantly associated with aggressive behavior and chemotherapeutic resistance in se...
Main Authors: | Xinke Zhang, Yingying Wang, Gari A, Chunhua Qu, Jiewei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.721030/full |
Similar Items
-
Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
by: Tilahun Ayane Debele, et al.
Published: (2020-12-01) -
Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy
by: Ben Wang, et al.
Published: (2020-05-01) -
Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma
by: Jiacheng Huang, et al.
Published: (2021-08-01) -
LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
by: Dagmar Zweytick
Published: (2019-11-01) -
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
by: Praveen Vikas, et al.
Published: (2020-04-01)